<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555525</url>
  </required_header>
  <id_info>
    <org_study_id>SEY1901</org_study_id>
    <nct_id>NCT04555525</nct_id>
  </id_info>
  <brief_title>A Pilot Study on the Use of Seysara for Rosacea</brief_title>
  <official_title>A Pilot Study on the Use of Seysara for Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, parallel group, randomized, investigator-blinded pilot study.&#xD;
      Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a&#xD;
      weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study&#xD;
      is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators&#xD;
      will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record&#xD;
      adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life&#xD;
      Quality Index.)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA (Investigator Global Assessment)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in inflammatory lesion count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA</measure>
    <time_frame>week 4</time_frame>
    <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA</measure>
    <time_frame>week 8</time_frame>
    <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change in inflammatory lesion count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Change in inflammatory lesion count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acne Rosacea</condition>
  <arm_group>
    <arm_group_label>sarecycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weight-based dose per label by mouth once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Centrum Adult Multivitamin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>one tablet by mouth daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sarecycline</intervention_name>
    <description>sarecycline tablet</description>
    <arm_group_label>sarecycline</arm_group_label>
    <other_name>Seysara</other_name>
    <other_name>sarecycline hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Centrum Adult Multivitamin</intervention_name>
    <description>Centrum Adult Mulltivitamin tablet</description>
    <arm_group_label>Centrum Adult Multivitamin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years of age&#xD;
&#xD;
          2. Moderate to severe rosacea (IGA score 3 or 4) on the proposed facial treatment area&#xD;
             consisting of:&#xD;
&#xD;
               1. At least 15 and not more than 50 facial papules and pustules, excluding lesions&#xD;
                  involving the eyes and scalp&#xD;
&#xD;
               2. No more than 2 nodules on the face&#xD;
&#xD;
          3. Presence or history of erythema and/or flushing of the face&#xD;
&#xD;
          4. If a female of child-bearing potential, have a negative urine pregnancy test and agree&#xD;
             to use an effective method of contraception. A sterile sexual partner is NOT&#xD;
             considered an adequate form of birth control&#xD;
&#xD;
          5. Willing to minimize external factors that might trigger rosacea flare-ups (eg, spicy&#xD;
             foods, thermally hot foods and drinks, hot environments, prolonged sun exposure,&#xD;
             strong winds, and alcoholic beverages&#xD;
&#xD;
          6. Subjects who use make-up must have used the same brands/types of make-up for a minimum&#xD;
             period of 14 days prior to study entry and must agree to use the same make-up,&#xD;
             brand/type, or frequency of use throughout the study&#xD;
&#xD;
          7. Completed and signed an appropriately administered Informed Consent Form (ICF) prior&#xD;
             to any study-related procedures -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Woman who is pregnant, lactating, or planning to become pregnant during the study&#xD;
             period&#xD;
&#xD;
          2. presence of any skin condition on the face that would interfere with the diagnosis or&#xD;
             assessment of rosacea&#xD;
&#xD;
          3. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe;) or plaque-like&#xD;
             facial edema&#xD;
&#xD;
          4. Excessive facial hair (eg, beards, sideburns, moustaches, etc) that would interfere&#xD;
             with diagnosis or assessment of rosacea&#xD;
&#xD;
          5. History of hypersensitivity or allergy to all tetracyclines, or to any other component&#xD;
             of the formulation&#xD;
&#xD;
          6. Patients with history of C-diff associated colitis, intracranial hypertension will be&#xD;
             excluded&#xD;
&#xD;
          7. Severe erythema, dryness, scaling, pruritis, stinging/burning, or edema&#xD;
&#xD;
          8. Use within 6 months prior to Day 0/Baseline of oral retinoids (eg, Accutane®) or&#xD;
             therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are&#xD;
             allowed)&#xD;
&#xD;
          9. Initiation of use of estrogens or oral contraceptives less than 3 months prior to Day&#xD;
             0/Baseline&#xD;
&#xD;
         10. Use within 1 month prior to Day 0/Baseline of:&#xD;
&#xD;
               1. Systemic antibiotics known to have an impact on the severity of facial rosacea&#xD;
                  (eg, containing tetracycline and its derivatives, erythromycin and its&#xD;
                  derivatives, sulfamethoxazole, or trimethoprim.) Subjects requiring systemic&#xD;
                  antibiotics not known to affect rosacea will be considered on a case-by-case&#xD;
                  basis&#xD;
&#xD;
               2. Systemic corticosteroids (Note: intranasal and inhalational corticosteroids do&#xD;
                  not require a washout and maybe used throughout the trial if the subject is on a&#xD;
                  stable dose.)&#xD;
&#xD;
         11. Use within 2 weeks prior to Day 0/Baseline of:&#xD;
&#xD;
               1. Topical corticosteroids&#xD;
&#xD;
               2. Topical antibiotics&#xD;
&#xD;
               3. Topical medications for rosacea (eg, metronidazole)&#xD;
&#xD;
         12. Use of sauna during the 2 weeks prior to Day 0/Baseline and during the study&#xD;
&#xD;
         13. Had wax epilation of the face within 2 weeks prior to Day 0/Baseline&#xD;
&#xD;
         14. Active bacterial folliculitis&#xD;
&#xD;
         15. Consumption of excessive alcohol, abuse of licit or illicit drugs, or a condition&#xD;
             that, in the opinion of the Investigator, could compromise the subject's ability to&#xD;
             comply with study requirements&#xD;
&#xD;
         16. Participation in activities that involve excessive or prolonged exposure to sunlight&#xD;
             or weather extremes, such as wind or cold&#xD;
&#xD;
         17. Presence of any clinically significant condition or situation, other than the&#xD;
             condition being studied, that in the opinion of the Investigator would interfere with&#xD;
             the study evaluations or optimal participation in the study&#xD;
&#xD;
         18. Participation in an investigational drug study (ie, subject has been treated with an&#xD;
             investigational drug) within 30 days prior to Day 0/Baseline. Subjects who are&#xD;
             participating in non-treatment studies such as observational studies or registry&#xD;
             studies can be considered for inclusion&#xD;
&#xD;
         19. Prior laser therapy (for telangiectasia or other conditions), electrodessication, or&#xD;
             phototherapy (eg, ClearLight ®) to the facial area within 180 days prior to Day&#xD;
             0/Baseline&#xD;
&#xD;
         20. Prior cosmetic procedures (eg, facials) that may affect the efficacy and safety&#xD;
             profile of the investigational product within 14 days prior to Day 0/Baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Skin Sciences, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <results_first_submitted>November 18, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derm Research, PLLC</investigator_affiliation>
    <investigator_full_name>L.H. Kircik, M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarecycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT04555525/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sarecycline</title>
          <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
        </group>
        <group group_id="P2">
          <title>Centrum Adult Multivitamin</title>
          <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sarecycline</title>
          <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
        </group>
        <group group_id="B2">
          <title>Centrum Adult Multivitamin</title>
          <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.42" spread="14.96"/>
                    <measurement group_id="B2" value="52.36" spread="13.47"/>
                    <measurement group_id="B3" value="52.41" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IGA (Investigator Global Assessment)</title>
        <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>IGA (Investigator Global Assessment)</title>
          <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Lesion Count</title>
        <description>Change in inflammatory lesion count</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Count</title>
          <description>Change in inflammatory lesion count</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80" spread="24"/>
                    <measurement group_id="O2" value="-60" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGA</title>
        <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>IGA</title>
          <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGA</title>
        <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>IGA</title>
          <description>Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA:&#xD;
0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Lesion Count</title>
        <description>Change in inflammatory lesion count</description>
        <time_frame>Baseline and Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Count</title>
          <description>Change in inflammatory lesion count</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56" spread="29"/>
                    <measurement group_id="O2" value="-31" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Lesion Count</title>
        <description>Change in inflammatory lesion count</description>
        <time_frame>Baseline and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarecycline</title>
            <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
          </group>
          <group group_id="O2">
            <title>Centrum Adult Multivitamin</title>
            <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Count</title>
          <description>Change in inflammatory lesion count</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71" spread="27"/>
                    <measurement group_id="O2" value="-44" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks average, from signing of Informed Consent until end of study participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sarecycline</title>
          <description>weight-based dose per label by mouth once daily for 12 weeks&#xD;
sarecycline: sarecycline tablet</description>
        </group>
        <group group_id="E2">
          <title>Centrum Adult Multivitamin</title>
          <description>one tablet by mouth daily for 12 weeks&#xD;
Centrum Adult Multivitamin: Centrum Adult Mulltivitamin tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>r ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>metallic taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>stomach bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>herpes simplex l lower lip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>respiratory syncytial virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>tinea versicolor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone spur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>generalized muscle soreness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>intermittent pain under r rib cage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>sleep apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Boil</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dry lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>facial sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dog bite r arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ingrown eyebrow hair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>rash of unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>sunburn on face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senen Pena</name_or_title>
      <organization>Skin Sciences, PLLC</organization>
      <phone>502-451-9000</phone>
      <email>spdermresearch@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

